JSS Investmentfonds II - JSS Sustainable Equity - Future Health I EUR accRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | - | - | -5.0 | -12.1 | 5.3 | |
+/-Cat | - | - | -0.3 | -9.0 | 1.5 | |
+/-B’mrk | - | - | -10.8 | -9.6 | -2.2 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 20/11/2024 | EUR 97.37 | |
Day Change | 0.96% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU2041626628 | |
Fund Size (Mil) 31/10/2024 | CHF 130.22 | |
Share Class Size (Mil) 31/10/2024 | EUR 4.97 | |
Max Initial Charge | - | |
Ongoing Charge 01/10/2024 | 1.17% |
Investment Objective: JSS Investmentfonds II - JSS Sustainable Equity - Future Health I EUR acc |
The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD). |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Simone Poma 01/07/2024 | ||
Jean-Charles Belvo 01/02/2022 | ||
Click here to see others | ||
Inception Date 26/01/2021 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
No benchmark | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JSS Investmentfonds II - JSS Sustainable Equity - Future Health I EUR acc | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.43 |
Danaher Corp | Healthcare | 5.66 |
Boston Scientific Corp | Healthcare | 5.07 |
Sanofi SA | Healthcare | 4.97 |
Novo Nordisk AS Class B | Healthcare | 4.31 |
Increase Decrease New since last portfolio | ||
JSS Investmentfonds II - JSS Sustainable Equity - Future Health I EUR acc |